- Home
- ACIU vs EVM Comparison
ACIU vs EVM Comparison
Compare ACIU & EVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EVM
- Stock Information
- Founded
- ACIU 2003
- EVM 2002
- Country
- ACIU Switzerland
- EVM United States
- Employees
- ACIU N/A
- EVM N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EVM Finance/Investors Services
- Sector
- ACIU Health Care
- EVM Finance
- Exchange
- ACIU Nasdaq
- EVM Nasdaq
- Market Cap
- ACIU 189.1M
- EVM 220.1M
- IPO Year
- ACIU 2016
- EVM N/A
- Fundamental
- Price
- ACIU $2.07
- EVM $8.66
- Analyst Decision
- ACIU Strong Buy
- EVM
- Analyst Count
- ACIU 1
- EVM 0
- Target Price
- ACIU $12.00
- EVM N/A
- AVG Volume (30 Days)
- ACIU 125.1K
- EVM 55.8K
- Earning Date
- ACIU 08-05-2025
- EVM 01-01-0001
- Dividend Yield
- ACIU N/A
- EVM 4.01%
- EPS Growth
- ACIU N/A
- EVM N/A
- EPS
- ACIU N/A
- EVM 0.20
- Revenue
- ACIU $32,014,254.00
- EVM N/A
- Revenue This Year
- ACIU N/A
- EVM N/A
- Revenue Next Year
- ACIU $533.21
- EVM N/A
- P/E Ratio
- ACIU N/A
- EVM $47.61
- Revenue Growth
- ACIU 91.20
- EVM N/A
- 52 Week Low
- ACIU $1.43
- EVM $7.67
- 52 Week High
- ACIU $4.26
- EVM $9.59
- Technical
- Relative Strength Index (RSI)
- ACIU 55.57
- EVM 38.72
- Support Level
- ACIU $2.00
- EVM $8.66
- Resistance Level
- ACIU $2.15
- EVM $9.02
- Average True Range (ATR)
- ACIU 0.13
- EVM 0.09
- MACD
- ACIU -0.01
- EVM -0.02
- Stochastic Oscillator
- ACIU 80.92
- EVM 13.89
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.